-
Product Insights
NewSystemic Aspergillosis – Drugs In Development, 2024
Empower your strategies with our Systemic Aspergillosis – Drugs In Development, 2024 report and make more profitable business decisions. Aspergillosis is an opportunistic infection that usually affects the lower respiratory tract and is caused by inhaling spores of the filamentous fungus Aspergillus, commonly present in the environment. The spores germinate and develop into hyphae, which enter blood vessels and, with invasive disease, cause hemorrhagic necrosis and infarction. Symptoms may be those of asthma, pneumonia, sinusitis, or rapidly progressing systemic illness. The...
-
Product Insights
NewNet Present Value Model: TFF Pharmaceuticals Inc’s TFF VORI
Empower your strategies with our Net Present Value Model: TFF Pharmaceuticals Inc's TFF VORI report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voriconazole in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voriconazole in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voriconazole in Asthma Drug Details: Voriconazole is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IPP-204106 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPP-204106 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IPP-204106 in Metastatic Breast Cancer Drug Details: IPP-204106 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lbvd in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lbvd in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Hepatitis B Drug Details:LBVD is under development for the prevention of...
-
Company Profile
TFF Pharmaceuticals Inc – Company Profile
TFF Pharmaceuticals Inc (TFF Pharmaceuticals) is a biopharmaceutical company that develops and commercializes inhalable solutions to treat respiratory diseases. The company is investigating TFF VORI, an inhaled dry powder drug targeting invasive pulmonary aspergillosis (IPA); TFF TAC-LAC, an inhaled dry powder used with an inhaler; and vaccines for influenza, ebola, Marburg, and alphaviruses. The company is also evaluating a dry powder formulation of Niclosamide against COVID-19. It utilizes its proprietary thin film freezing (TFF) technology platform to improve the solubility...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Net Present Value Model: TFF Niclosamide (COVID-19)
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TFF Niclosamide (COVID-19) Drug Details Niclosamide...